Early fecal calprotectin levels at week 8 may guide therapeutic decisions on Ustekinumab therapy in patients with Crohn's disease.
Sign Up to like & getrecommendations! Published in 2023 at "Scandinavian journal of gastroenterology"
DOI: 10.1080/00365521.2023.2194009
Abstract: BACKGROUND Response evaluation after induction therapy with ustekinumab (UST) in Crohn's disease (CD) is important for decisions on maintenance therapy. We aimed to assess the potential of fecal calprotectin (FC) levels to predict endoscopic response… read more here.
Keywords: endoscopic response; therapy; crohn disease; fecal calprotectin ... See more keywords
PS02.086: ENDOSCOPIC RESPONSE EVALUATION OF NEOADJUVANT CHEMOTHERAPY CAN PREDICT PATHOLOGICAL RESPONSE AND SURVIVAL IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Sign Up to like & getrecommendations! Published in 2018 at "Diseases of the Esophagus"
DOI: 10.1093/dote/doy089.ps02.086
Abstract: To investigate the association between endoscopic response evaluation of neoadjuvant chemotherapy (NAC) with pathological response and survival in patients with esophageal squamous cell carcinoma (ESCC). We retrospectively reviewed the medical records of patients with the… read more here.
Keywords: response; endoscopic response; pathological response; response evaluation ... See more keywords
Fecal Microbiota Alterations Associated With Clinical and Endoscopic Response to Infliximab Therapy in Crohn's Disease.
Sign Up to like & getrecommendations! Published in 2020 at "Inflammatory bowel diseases"
DOI: 10.1093/ibd/izaa253
Abstract: BACKGROUND Gut microbiota dysbiosis is associated with the occurrence and development of Crohn disease (CD). Currently, infliximab (IFX) is used more and more to treat CD; however, gut microbiota alterations during IFX therapy are variable… read more here.
Keywords: week; response; microbiota; clinical endoscopic ... See more keywords